MedTrace Logo

The Effect of GIP(3-30)NH2

NCT03770910 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 8

Last updated 2020-03-26

No results posted yet for this study

Summary

Infusion of glucose-dependent insulintropic polypeptide (GIP) receptor antagonist and evaluation of effect of insulin secretion in healthy subjects.

Conditions

  • Endocrine - Other

Interventions

OTHER

GIP receptor antagonist

GIP receptor antagonist

OTHER

GIP receptor agonist

GIP(1-42)

OTHER

Saline

Placebo (vehicle for infusions)

Sponsors & Collaborators

  • Steno Diabetes Center Copenhagen

    collaborator OTHER

  • University of Copenhagen

    collaborator OTHER

  • University Hospital, Gentofte, Copenhagen

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
DOUBLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-12-06
Primary Completion
2019-03-01
Completion
2019-12-01

Countries

  • Denmark

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03770910 on ClinicalTrials.gov